China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...

On Monday, for the second time in as many business days, Illumina ( ILMN -4.11%) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost 6% ...

A stand-alone sequencing approach was accurate, cost effective and efficient for analyzing resistant pathogens and ...

Gene sequencing machine maker Illumina forecast 2025 revenue largely below Wall Street estimates on Thursday, signaling ...

The local gene-sequencing company and a U.S. clothing company face sales restrictions in China as part of that country’s ...

Genomic sequencing specialist Illumina (NASDAQ: ILMN) was something of a victim in the U.S.-China trade spat on Tuesday.

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

Analysts said the move comes amid rising trade tensions with the U.S. and as Illumina faces stiff competition in China’s ...

Illumina shares tumbled 8% Friday on investor concerns about the future of the gene-sequencing equipment maker’s business in ...

Founded in 1998, Illumina (NASDAQ:ILMN) is a provider of genomic sequencing and analysis technologies for applications in research, clinical diagnostics, and life sciences. Genomics and sequencing ...

The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...